Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Investment analysts at B. Riley boosted their FY2017 earnings per share (EPS) estimates for Supernus Pharmaceuticals in a note issued to investors on Wednesday. B. Riley analyst D. Buck now forecasts that the specialty pharmaceutical company will earn $1.08 per share for the year, up from their previous forecast of $1.05. B. Riley currently has a “Buy” rating and a $50.00 target price on the stock. B. Riley also issued estimates for Supernus Pharmaceuticals’ Q4 2017 earnings at $0.27 EPS, Q1 2018 earnings at $0.18 EPS, Q2 2018 earnings at $0.39 EPS, Q4 2018 earnings at $0.50 EPS, FY2018 earnings at $1.55 EPS and FY2019 earnings at $2.25 EPS.

Several other brokerages also recently weighed in on SUPN. Stifel Nicolaus downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 target price for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reissued a “hold” rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. FBR & Co began coverage on shares of Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price objective for the company. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $47.00 price objective for the company in a report on Wednesday. Finally, BidaskClub raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $49.60.

COPYRIGHT VIOLATION WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Expected to Earn FY2017 Earnings of $1.08 Per Share” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-expected-to-earn-fy2017-earnings-of-1-08-per-share/1694977.html.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at $37.25 on Thursday. The firm has a market cap of $1,873.63, a price-to-earnings ratio of 34.48, a P/E/G ratio of 1.55 and a beta of 1.30. The company has a quick ratio of 1.74, a current ratio of 1.82 and a debt-to-equity ratio of 0.01. Supernus Pharmaceuticals has a 1-year low of $20.33 and a 1-year high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. The company had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company’s quarterly revenue was up 41.5% compared to the same quarter last year.

In other news, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the sale, the senior vice president now directly owns 12,500 shares in the company, valued at approximately $623,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the sale, the vice president now owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Insiders have sold a total of 153,709 shares of company stock valued at $7,223,108 in the last three months. Insiders own 6.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in SUPN. Meeder Asset Management Inc. raised its position in shares of Supernus Pharmaceuticals by 3,455.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares in the last quarter. Advisor Group Inc. raised its position in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares in the last quarter. Hedge funds and other institutional investors own 96.11% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.